**Introduction**

As older adults are among the fastest growing populations living with HIV, it is essential to evaluate efficacy and safety of ART in this demographic, which has historically been underrepresented in HIV studies.1-3

- Addressing treatment needs for older adults requires managing age-related comorbidities and polypharmacy while maintaining virologic suppression.4
- DTG/3TC is a global, international, randomized, placebo-controlled, double-blind, active-controlled study that demonstrated efficacy and safety of DTG/3TC compared to current antiretroviral regimen (CAR) in participants aged ≥50 years.5
- Here, we evaluate the efficacy and safety of DTG/3TC in a larger set of participants aged ≥50 years in a pooled analysis of TANGO and SALSA.

**Methods**

- This pooled analysis includes 48-week data from the phase 2 TANGO and SALSA clinical trials in adults (Figure 1).6
- Primary and key secondary endpoints were proportions of participants with HIV RNA <50 c/mL, and ≤100 c/mL, respectively, at Week 48 (Snapshot, ITT E population) using a Cochran-Mantel-Haenszel analysis adjusting for baseline third agent class.
- Mixed-effects repeated measures analysis was used for adjusted mean change from baseline in CD4+ cell count, CD4+/CD8+ ratio, weight, renal biomarkers, and lipids.
- Adjustment terms were treatment, site, age, sex, race, non-african american race, baseline viral load, baseline third agent class, treatment-by-interaction, baseline value-by-by subject value interaction, and cell counts as operated on cell counts. Additional adjustment terms included age by sex, age by treatment, age by site, and baseline viral load by site interaction.
- Additional adjustment terms are shown below tables and figures as applicable.

**Results**

- **Table 1. Baseline Characteristics**

  **Table 2. Adjusted Mean Change From Baseline to Week 48 in CD4 Cell Count and CD4+/CD8+ Ratio: TANGO and SALSA Pooled ITT-E Population**

  **Figure 1. Study Design**

- **Figure 2. Proportions of Participants With HIV-1 RNA <50 c/mL by Age and Overall: TANGO and SALSA Pooled ITT-E Population**

- **Figure 3. Change From Baseline in Plasma/ Serum cGPR and Week 48 by Age: TANGO and SALSA Pooled ITT-E Population**

- **Figure 4. Change From Baseline in Fasting Lipids (Log-Transformed) at Week 48: TANGO and SALSA Pooled ITT-E Population**

- **Table 3. Summary of AEs Through Week 48 by Age: TANGO and SALSA Pooled ITT-E Population**

- **Table 4. Adjusted Mean Change From Baseline to Week 48 in Weight: TANGO and SALSA Pooled ITT-E Population**

**Conclusions**

- Although participants aged ≥50 years used a higher number of concomitant medications, had a greater prevalence of comorbidities, and a longer duration of prior ART, pooled findings from 2 clinical trials demonstrated that DTG/3TC maintained high rates of virologic suppression after treatment switch with no reported resistance, similar changes in CD4+ cell count and CD4+/CD8+ ratio, and favorable lipid profiles compared to continuing CAR.
- DTG/3TC is a robust switch option for older adults living with HIV with fewer antiretroviral drugs.
This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their licence. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.